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Individual posttranslational modifications (PTMs) of
p53 mediate diverse p53-dependent responses;
however, much less is known about the combi-
natorial action of adjacent modifications. Here, we
describe crosstalk between the early DNA damage
response mark p53K382me2 and the surrounding
PTMs that modulate binding of p53 cofactors,
including 53BP1 and p300. The 1.8 A˚ resolution
crystal structure of the tandem Tudor domain
(TTD) of 53BP1 in complex with p53 peptide
acetylated at K381 and dimethylated at K382
(p53K381acK382me2) reveals that the dual PTM in-
duces a conformational change in p53. The a-helical
fold of p53K381acK382me2 positions the side chains
of R379, K381ac, and K382me2 to interact with TTD
concurrently, reinforcing a modular design of double
PTM mimetics. Biochemical and nuclear magnetic
resonance analyses show that other surrounding
PTMs, including phosphorylation of serine/threonine
residues of p53, affect association with TTD. Our
findings suggest a novel PTM-driven conformation
switch-like mechanism that may regulate p53 inter-
actions with binding partners.
INTRODUCTION
p53 undergoes numerous posttranslationalmodifications (PTMs)
that mediate function, stability, and subcellular localization of
this tumor suppressor. Recent mass-spectrometry analysis has
identified 222 PTMs present on 99 residues of endogenous p53
(DeHart et al., 2014). The PTMsare spread throughout the protein
but are particularly enriched in the C-terminal regulatory domain
(CTD) of p53. Among the most common PTMs are phosphoryla-
tion of serine and threonine residues, methylation of arginine
residues, and acetylation, methylation, ubiquitination, sumoyla-322 Structure 23, 322–331, February 3, 2015 ª2015 Elsevier Ltd All rtion, and neddylation of lysine residues (Berger, 2010; Dai and
Gu, 2010). In general, phosphorylation and acetylation are
thought to activate or stabilize p53, whereas polyubiquitination
targets p53 for proteasomal degradation, and methylation can
be either an activating or repressivemark. Although some individ-
ual PTMs are linked to a particular p53 response, growing evi-
dence suggests widespread crosstalk between the PTMs, which
could be either synergistic or antagonistic in nature.
The p53 CTD contains six lysines within a span of 17 residues,
including two pairs of contiguous lysine residues, K372K373
and K381K382. As individual lysine residues can be posttrans-
lationally modified in a variety of ways, crosstalk between
these PTMs can provide a mechanism for fine-tuning p53 activ-
ities. For example, in response to DNA damage, SET7/9-depen-
dent monomethylation of K372 can promote acetylation of
nearby lysine residues, including K373 and K382, and enhance
the stability and activity of p53, ultimately upregulating p21
and triggering cell-cycle arrest (Ivanov et al., 2007). Methylation
of K369 in mouse p53 (K372 in human ortholog) is important
for the recruitment of the Tip60 lysine acetyltransferase (KAT)
complex to p53 and for the subsequent acetylation of K370
and K379 (K373 and K382 in human p53) (Kurash et al., 2008).
In the absence of sustained damage, repressive methylation
marks have been proposed to keep p53 in an inactive form;
however, upon DNA damage, acetylation can replace methyl-
ation, promoting p53 transcriptional activity (Berger, 2010;
Loewer et al., 2010). In agreement, activities of SMYD2
and SET8 lysine methyltransferases (KMTs) responsible for the
deposition of the repressive marks p53K370me1 (p53 monome-
thylated at K370) and p53K382me1 (p53 monomethylated at
K382) are reduced following DNA damage, while activity of the
CBP/p300 KAT is increased (Huang et al., 2006, 2007; Ivanov
et al., 2007; Loewer et al., 2010; Shi et al., 2007; West et al.,
2010). The acetylation-methylation interplay can function as a
switch, allowing for distinctly different p53 responses to severe
DNA damage as opposed to transient low-level DNA breaks
that occur during normal cell processes (Berger, 2010; Loewer
et al., 2010).
A number of spatial and temporal correlations have been
reported within the p53 methylation or acetylation pathways.ights reserved
The SET7/9-produced activating mark p53K372me1 (p53
monomethylated at K372) prevents repressive monomethyla-
tion of K370 by inhibiting SMYD2 priming at p53 (Huang
et al., 2006, 2007). Acetylation of the CTD lysine residues stim-
ulates p53 transactivation through the recruitment of cofac-
tors, inhibits ubiquitin ligase MDM2-mediated ubiquitination,
and is essential for p53 tetramer formation (Barlev et al.,
2001; Itahana et al., 2009; Kawaguchi et al., 2006; Luo et al.,
2004; Mujtaba et al., 2004; Yamaguchi et al., 2009). Binding
of p53 to the transcriptional coactivator PC4 is augmented
when K381 and K382 are acetylated (Debnath et al., 2011).
Acetylation of p53 by Tip60 selectively impedes MDM2-
dependent neddylation, whereas FBXO11-facilitated neddyla-
tion suppresses p53 transcriptional activity, possibly via
preventing acetylation (Abida et al., 2007; Dohmesen et al.,
2008). Sumoylation at K386 blocks consecutive acetylation
of p53 by p300, while acetylation shows no antagonistic effect
on sumoylation at K386 and alleviates sumoylation-induced
inhibition of DNA binding. Genotoxic stress triggers phosphor-
ylation of S366, S378, and T387, which differentially affect
p53 acetylation (Ou et al., 2005). Phosphorylation of S378 de-
creases acetylation of K373 and K382, whereas phosphoryla-
tion of S366 and T387 increases it (Ou et al., 2005).
Three histone readers, including the malignant brain tumor
(MBT) module of the L3MBTL1 protein, the tandem Tudor
domain (TTD) of the PHF20 protein, and the TTD of p53-binding
protein 1 (53BP1), have been shown to recognize methylated
K382 of p53 (Cui et al., 2012; Kachirskaia et al., 2008; Roy
et al., 2010; Shi et al., 2007; West et al., 2010). p53 monome-
thylated at K382 is generated by the SET8 KMT, which is active
in resting cells but is repressed following DNA damage (Shi
et al., 2007). In the absence of stress, the MBT module of
L3MBTL1 binds to p53K382me1 at promoters of the highly
responsive p53 targets, p21 and PUMA, repressing these
genes and compacting chromatin (Shi et al., 2007; West
et al., 2010). The concomitant decrease in p53K382me1 levels
and the increase in p53K382me2 (p53 dimethylated at K382)
levels upon DNA damage cause disassociation of L3MBTL1.
The dimethylated p53K382 species is recognized by the
TTD of 53BP1, a DNA damage response protein and a p53
cofactor that also binds to H4K20me2 (histone 4 dimethylated
at K20) (Botuyan et al., 2006; Huang et al., 2007; Huyen et al.,
2004; Kachirskaia et al., 2008). 53BP1 association with
p53K382me2 has been shown to facilitate p53 accumulation
and stabilization at DNA double-strand break (DSB) sites and
play a role in DNA repair (Kachirskaia et al., 2008; Roy et al.,
2010).
In this study, we characterize crosstalk between PTMs in
the K381K382 region and the surrounding residues of p53.
We demonstrate that dimethylation of p53K382 is rapidly
induced following DNA damage, whereas acetylation of
p53K381 remains relatively unchanged. The TTD domain of
53BP1 recognizes the p53K381acK382me2 (p53 acetylated at
K381 and dimethylated at K382) modification. This dual PTM
causes a significant conformational change in the p53 structure,
converting a U-shaped p53K382me2 peptide into a-helical
p53K381acK382me2. Other PTMs, including phosphorylation
of serine and threonine residues of p53, further influence the
interaction with 53BP1 TTD. Our data suggest a novel p53Structure 23, 32regulatory mechanism in which different combinations of PTMs
trigger distinct p53 conformations when bound to specific
interactors.
RESULTS AND DISCUSSION
p53K382me2 Is an Early DNA Damage Response PTM
Dimethylated K382 was identified as a DNA damage-associated
PTM of p53 (Kachirskaia et al., 2008); however, the dynamics of
this PTM have not been investigated. We used immunoblot anal-
ysis to examine the occurrence of p53K382me2 in human U2OS
osteosarcoma cells in the context of the well-characterized
response to ionizing radiation (IR). As expected, the levels of total
and phospho-Ser15 p53 increased during 4 hr after exposure
to 5 Gy IR, indicating increased stability and activation of p53
(Figure 1A). The level of the cyclin-dependent kinase inhibitor,
p21 (CDKN1A), a transcriptional target of p53, was sharply
elevated at 4 hr after exposure to IR. In agreement with previous
reports (Kachirskaia et al., 2008), p53K382me2 was undetect-
able in untreated cells, however its level increased considerably
0.5 hr after DNA damage, indicating that dimethylation of K382 is
a PTM elicited early in the response to DNA damage (Figure 1B).
The p53K382me2 level continued rising 1 hr after irradiation,
reduced at 2 hr, and increased again at 4 hours, revealing that
this modification is subject to regulation. The dynamic nature
of p53K382me2 levels following exposure to IR resembles oscil-
lations in the activity of Set7/9 after DNA damage (Ivanov et al.,
2007), as well as ATM activity, p53 levels, and p53 transcriptional
target levels that result from reactivation of DNA damage
response signaling by the presence of persistent DNA damage
(Batchelor et al., 2008).
To demonstrate that the increase in p53K382me2 levels is a
general response to DNA damage, we treated U2OS cells with
doxorubicin, a chemotherapeutic agent that induces DSBs in
DNA, and with Trichostatin A (TSA), a broad-spectrum deacety-
lase inhibitor. As shown in Figure 1C and Figure S1A (available
online), little p53K382me2 was present in cells under basal
conditions, either with or without TSA treatment. However, the
p53K382me2 level increased substantially in p53 immunopre-
cipitated from cells treated with doxorubicin. Unexpectedly,
we found that anti-p53K382me2 antibodies showed higher reac-
tivity toward p53 immunoprecipitated from cells treated with
both doxorubicin and TSA, even though the total amount of
p53, as detected by DO-1 antibodies, remained essentially the
same. These results suggest that acetylation of p53 may affect
anti-p53K382me2 antibody reactivity.
In general, acetylation of p53 has been shown to increase in
response to DNA damage and correlate with p53 activation
and stabilization (Barlev et al., 2001; Luo et al., 2004; Tang
et al., 2008); however, DNA damage-dependent behavior of
p53K381ac (p53 acetylated at K381) has not been characterized.
We found that in contrast to p53K382me2, the level of
p53K381ac in U2OS cells remained relatively unaffected by the
exposure to IR (Figures 1A and 1B). As anticipated, treatment
of U2OS cells with TSA +/ doxorubicin significantly elevated
the p53K381ac level (Figure S1B). Together, the DNA
damage assays reveal that the presence of acetylated K381
may influence the recognition of dimethylated K382 by anti-
p53K382me2 antibodies.2–331, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 323
Figure 1. p53K382me2 Is an Early DNA
Damage Response PTM
(A) Immunoblot analysis of whole-cell extract (WCE)
or immunoprecipitated (IP) proteins from U2OS
cells following exposure to IR using the indicated
antibodies. Cells were left untreated or were
exposed to 5 Gy IR and harvested at the indicated
times. p53 proteins were immunoprecipitated by
agarose-conjugated DO1 antibodies. The lower of
the two bands detected by the anti-p53K381ac
antibody comigrates with the bands detected by
the anti-p53 (DO-1) and anti-p53S15p antibodies.
(B) A graph of the relative levels of total p53 and
p53 bearing K381ac and K382me2 modifications
following exposure to IR. Relative protein levels
are based on immunoblot analysis. The relative
levels of total p53 (DO-1 reactivity) and p53K381ac
inWCEare given relative to b-actin levels (left axis);
the relative levels of anti-p53K382me2 reactivity in
the IP material are given relative to the total p53
(DO-1) level recovered in the IPmaterial (right axis).
Protein-level ratios were normalized to the value in
the untreated samples. Quantitation of p53K381ac
levels was based on the integrated signal intensity
for the lower band only.
(C) Immunoblot analysis ofWCEor IP proteins from
U2OS cells using the indicated antibodies. Cells
were treated without or with 5 mg/ml doxorubicin
(Dox) for 4 hr, either in the absence or presence of
400 nM Trichostatin A (TSA) for the last 1 hr before
harvest. p53 proteins were immunoprecipitated by
agarose-conjugated DO1 antibodies.
(D) Dot-blot analysis of anti-p53K382me2 antibody
and anti-p53K381ac antibody reactivities toward
p53 peptides containing K381ac and K382me2
combinations.
(E) Microarray analysis of anti-p53K382me2 anti-
body reactivity for the indicated p53 peptides.
Data are presented as normalized mean intensities
from six individual spots per peptide. Error is pre-
sented as SEM. See also Figure S1.Acetylation of K381 Enhances Reactivity of Anti-
p53K382me2 Antibodies
Wenote that the anti-p53K382me2 antibodieswere raised in rab-
bits immunized with p53K382me2 peptide containing residues
377–387 of human p53, and were positively selected for binding
to p53K382me2 peptide and negatively selected for binding to
unmodified p53 peptide (Kachirskaia et al., 2008); however, the
effect of acetylation of the adjacent K381 residue on the antibody
reactivity was not examined. To investigate the role of K381
acetylation, we synthesized unmodified p53 peptide (residues
377–386), and p53 peptides carrying single modifications,
p53K381ac or p53K382me2, and the double modification
p53K381acK382me2, and tested them in dot-blot assays. As
shown in Figure 1D, the generated anti-p53 antibodies strongly
recognized the p53K381acK382me2 peptide, reacted 16-fold
more weakly with the p53K382me2 peptide, and did not interact
with unmodified p53 or p53K381ac peptides. In contrast, the
anti-p53K381ac antibodies recognized p53K381ac and
p53K381acK382me2 peptides almost equally well.
To verify the anti-p53K382me2 antibody selectivity, we syn-
thesized an expanded series of biotinylated p53 CTD peptides
(residues 366–390) and printed them on streptavidin-coated324 Structure 23, 322–331, February 3, 2015 ª2015 Elsevier Ltd All rglass slides for microarray analysis. In agreement with the dot-
blot results, the anti-p53K382me2 antibodies reacted preferen-
tially with the p53K381acK382me2 peptide over unmodified,
p53K382me2, p53K370me2, and p53K372me2 peptides (Fig-
ure 1E). Importantly, acetylation at K386 or phosphorylation at
T377 or S378 did not enhance recognition of K382me2. The
higher reactivity of the generated anti-p53 antibodies toward
peptides containing both K381ac and K382me2 modifications
suggest that acetylation at K381 alters the p53 conformation
such that it enhances antibody binding, although we cannot
rule out the possibility that the immunogen was subjected to
acetylation at K381 in vivo.
DNA Damage Promotes Colocalization of p53 and p300
p53 is acetylated by p300/CBP at multiple lysine residues
including K381 in the CTD (Luo et al., 2004; Tang et al., 2008)
(Figure 2A). To establish whether DNA damage promotes coloc-
alization of p53 and p300, we analyzed changes in genome-wide
association of these proteins using publicly available data sets.
The p53 binding sites before and after DNA damage have
recently been identified (Lee et al., 2010; Li et al., 2012). p53
binds to 7,800 regions in untreated mouse embryonic stemights reserved
Figure 2. DNA Damage Promotes Colocali-
zation of p53 and p300
(A) Scheme of p53 K381 and K382 modifications in
the context of the DNA damage response.
(B) Pie chart displaying p53 overlap on p300-bound
regions in mouse ES cells before and after DNA
damage. p < 0.0002 by Fisher’s exact test. Asterisk
denotes p53 sites defined by Li et al. (2012).
(C) Normalized p300 ChIP-seq tag density sur-
rounding the center of p53 bound regions. Graphs
include 2 kb upstream and downstream of the
center of p53-bound regions.
(D) Gene ontology (GO) of p53/p300 regulated
genes upon DNA damage. Biological processes
include responses to oxidative stress, which may
correlate with dimethylation of K382, as well as
regulatory and development processes, whichmay
correlate with p53-activating PTMs, including
acetylation of multiple lysine residues and dime-
thylation of K370. DAVID-generated GO processes
withp values<0.05were reanalyzedusingREVIGO.
(E) Superimposed 1H,15N HSQC spectra of BD of
p300 collected during titration with p53K381ac
peptide (left) and p53K381acK382me2 peptide
(right). Spectra are color coded according to the
protein/peptide molar ratio.
(F) Representative binding curves used to deter-
mine the KD values by NMR.(ES) cells; however, under stress the number of p53-bound re-
gions increases to 52,000 (Li et al., 2012). Using the p300/
CBP ChIP-seq data from mouse ES cells generated by the
ENCODE consortium, we examined whether p53 colocalizes
with the regions occupied by p300/CBP (Consortium et al.,
2012). Under basal conditions, p53 associated with only 3%
of p300-bound regions (914 of 23,654 regions) (Figure 2B). In
response to stress, p53 and p300 colocalization increased
substantially, with p53 occupying 23% of p300-bound regions
(5,506 of 23,654; p < 0.0002). In agreement with these results,
meta-analysis of p53 target regions showed enrichment of
p300/CBP in cells treated with adriamycin (a trade name for
doxorubicin) (Figure 2C). Gene ontology analysis revealed that
p53/p300 colocalization occurs at genes involved in response
to oxidative stress, as well as regulation and development (Fig-
ure 2D). Together, these analyses suggest a synergistic activity
of p53 and p300/CBP in modulating cellular processes upon
DNA damage.
Binding of bromodomain (BD) of CBP to p53K382ac (p53
acetylated at K382) has been found to contribute to stabiliza-
tion of the CBP-p53 complex at chromatin, leading to acety-
lation of histones and p53 transactivation (Mujtaba et al.,
2004; Zeng et al., 2008). Interestingly, BD of CBP displays
selectivity for K382 and does not recognize p53 acetylated at
K320 or K373 (Mujtaba et al., 2004). To determine whether
p53K381acK382me2 can recruit BD-containing cofactors, weStructure 23, 322–331, February 3, 2015examined interaction of the p300 BD
with acetylated p53 peptides by nuclear
magnetic resonance (NMR). Titration of
either p53K381acK382me2 peptide or
p53K381ac peptide into 15N-labeled BD
of p300 led to substantial resonancechanges in the 1H,15N heteronuclear single quantum coherence
(HSQC) spectra of BD, implying that BD recognizes both pep-
tides (Figure 2E). Binding affinities of the p300 BD, measured
via chemical shift perturbation analysis, were found to be
241 mM and 282 mM for p53K381ac and p53K381acK382me2,
respectively (Figure 2F). These affinities were in the same range
as the binding affinity of CBP BD for p53K382ac (dissociation
constant [KD] of 187 mM) (Zeng et al., 2008). These results indi-
cate that p53K381ac can serve as a docking site for BD and
that dimethylation of K382 slightly diminishes binding of BD to
p53K381ac. Much like interaction of CBP BD with p53K382ac
(Mujtaba et al., 2004; Zeng et al., 2008), the p300 BD-
p53K381ac association can stabilize the p300-p53 complex,
though the BD can be displaced from p53K381acK382me2 by
the TTD module of 53BP1, which binds to this dual PTM more
strongly (see below).
K381acK382me2 Induces an a-Helical Structure in p53
The TTD of 53BP1 has been shown to bind to p53K382me2 in
response to DNA damage (Kachirskaia et al., 2008); therefore,
we examined the effect of K381 acetylation on recognition of
this PTM by TTD. Although acetylation causes significant
changes in the size and electrostatic properties of the lysine
side chain, we found that K381ac has only a small effect on
the binding free energy (Figure 3). The KD value measured by
fluorescence spectroscopy was estimated to be 760 nM forª2015 Elsevier Ltd All rights reserved 325
Figure 3. Molecular Basis for the Recogni-
tion of p53K381acK382me2 by TTD
(A) Binding affinities of wild-type (WT) and mutated
53BP1 TTD for the indicated histone peptides
measured by tryptophan fluorescence. * Measured
by NMR; ** Taken from Roy et al. (2010).
(B) Representative binding curves used to deter-
mine the KD values by fluorescence spectroscopy.
(C) Superimposed 1H,15N HSQC spectra of 53BP1
TTD recorded as p53K381acK382me2 peptide was
titrated. Spectra are color coded according to the
protein/peptide molar ratio.
(D) The normalized chemical shift changes in
1H,15N HSQC spectra of TTD induced by
p53K381acK382me2 peptide as a function of
residue. Residues showing large differences in
chemical shift are labeled. Differences greater than
the average plus one SD, the average plus one-half
SD, and the average are shown in red, orange, and
yellow, respectively. See also Figures S2 and S3.the interaction of the TTD with p53K381acK382me2 peptide and
was comparable with the KD of 900 nM determined for the inter-
action with p53K382me2 (Figures 3A and 3B; Roy et al., 2010).
To obtain molecular insight into the association with the dual
PTM, we cocrystallized the TTD with p53K381acK382me2 pep-
tide and determined a 1.8 A˚ resolution structure of the complex
(Figure 4 and Table 1). The structure reveals a canonical TTD fold
containing a pair of b barrels closely coupled through a C-termi-
nal a helix (Figures 4A and 4B). The p53K381acK382me2 peptide
folds in an a helix and is positioned near the top of the first b bar-
rel. The a helix is stabilized through the characteristic pattern of
backbone carbonyl-amide hydrogen bonds involving R379,
K381ac, K382me2, L383, and F385 residues of the peptide.
The a-helical structure of the p53K381acK382me2 peptide
places R379, K381ac, and K382me2 on the same face of the a
helix, thereby allowing the side chains of these residues to
interact with the TTD simultaneously in a tentacle-like manner.
The three side chains adopt an extended conformation and are
inserted deeply into separate binding pockets (Figures 4B and
4C). The guanidinium moiety of R379 is restrained by two
hydrogen bonds, one formed with the carboxylic group of
E1551 and another formed with the carboxylic group of D1521.
The dimethylated K382 occupies an aromatic pocket consisting
of four aromatic residues and an aspartate. The aromatic rings of
W1495, Y1502, F1519, and Y1523 are arranged almost perpen-
dicular to each other and are involved in cation-p interactions
with the positively charged dimethylammonium group of K382.
The hydrogen bond seen between this group and the carbox-
ylate of D1521 likely accounts for the preference of TTD for the
dimethyllysine substrate. The neutral side chain of K381ac is
bound in an adjacent aromatic/hydrophobic pocket formed by
Y1500, F1553, and I1587. The side chain amide of K381ac is
hydrogen bonded to the hydroxyl group of Y1502. In addition,326 Structure 23, 322–331, February 3, 2015 ª2015 Elsevier Ltd All rights reservedthe N terminus of the peptide is restrained
through the transient polar interaction be-
tween the hydroxyl group of S378 and the
carboxyl of E1551.
We compared the structures of TTD
bound to the p53K381acK382me2 andp53K382me2 peptides and found that 53BP1 uses different
mechanisms to recognize each of these PTM-containing p53 se-
quences (Figure 4D). In the p53K382me2 complex, the p53 pep-
tide is bound in a U-shape conformation, with its N terminus posi-
tioned near the rim of the second b barrel and the C terminus
traced between the b barrels (see the accompanying paper by
Tong et al., 2015 in this issue of Structure). In contrast, the
p53K381acK382me2 sequence is bound in a different orientation
and lies across theopenendof the firstbbarrel. Apart from recog-
nition of the dimethylammonium group of K382 through the aro-
matic cage, no similarity in coordination of any other p53 residue
is seen in the p53K381acK382me2-TTD and p53K382me2-TTD
complexes. The fact that K381acK382me2 induces such a
dramatic conformational change in the p53 CTD structure,
transforming a loop into an a helix, suggests a PTM-driven con-
formation switch that may regulate p53.
Molecular Mechanism of the p53K381acK382me2-TTD
Interaction
To assess the roles of the separate binding pockets in recogni-
tion of the K381ac and K382me2 modifications, we tested inter-
actions of the TTD by NMR and tryptophan fluorescence. Large
chemical shift changes in 1H,15N HSQC spectra of 15N-labeled
TTD were observed upon addition of p53K381acK382me2
peptide (Figure 3C). Plotting chemical shift changes for each
backbone amide of TTD allowed us to identify the protein re-
gions that were most affected due to binding in solution (Fig-
ure 3D). In agreement with the crystal structure of the complex,
residues of the K382me2-binding aromatic cage, such as
W1495, Y1523, and D1521, and adjacent residues were affected
to the highest degree. Resonances of the K381ac-binding
pocket residues, Y1500 and F1553, were also substantially
perturbed.
Figure 4. The Crystal Structure of the 53BP1 TTD-p53K381acK382me2 Complex
(A and B) TTD is shown as a ribbon diagram (A) and a solid surface (B) with the peptide depicted as a yellow ribbon. Residues of TTD forming the binding sites for
R379, K381ac, and K382me2 of the p53 peptide are colored green, salmon, and blue, respectively.
(C) A close view of the R379-, K381ac-, and K382me2-binding pockets. Dashed lines represent intermolecular hydrogen bonds.
(D) Structural overlay of the p53K381acK382me2 peptide (yellow) bound to TTD and p53K382me2 peptide (gray) bound to TTD (see the accompanying paper by
Tong et al., 2015 in this issue of Structure). TTD is not depicted for clarity.A close comparison of chemical shift perturbations in the TTD
upon binding to p53K381acK382me2 and p53K382me2 re-
vealed that both peptides induce the most significant changes
in the K382me2-binding cage (Figure 3D). The essential role of
the cage residues was substantiated through mutational anal-
ysis. Substitution of Y1502 with alanine reduced binding of
TTD to p53K381acK382me2 by about 14-fold, whereasmutation
of W1495 to alanine completely abrogated this interaction (Fig-
ure 3A; Figure S2).
NMR resonances of residues in the second b barrel, including
the K381ac-binding site residue F1553, were less perturbed
upon binding to p53K381acK382me2 as compared with binding
to p53K382me2. By contrast, another K381ac-binding site
residue, Y1500, was perturbed to a greater extent upon titration
with p53K381acK382me2. Replacement of Y1500 and F1553
individually or in combination weakened the interaction with
p53K381acK382me2 by 6-, 8-, and 37-fold, respectively,
corroborating the significance of the K381ac-binding site (Fig-
ure 3A). We note that in the absence of the K382me2 mark, the
wild-type TTD associates with p53K381ac peptide very weakly
(KD >5 mM) (Figure S3).Structure 23, 32The carboxyl group of D1521 forms hydrogen bonds with
K382me2 and R379 of the p53K381acK382me2 peptide, tightly
locking the side chains of both p53 residues. When D1521 was
mutated to a tyrosine to preserve the K382me2-binding aromatic
cage but eliminate contact with R379, the binding affinity of TTD
decreased 9-fold. Alanine substitution of D1521 led to a 83-
fold reduction in affinity for p53K381acK382me2, implying that
the D1521A mutant is unable to make favorable contacts with
either K382me2 or R379 of the peptide. Together, these data
indicate that proper coordination of not only K382me2 but also
K381ac and R379 is necessary for strong binding of TTD.
Acetyl-Methyllysine Switches Mediate Binding
of the 53BP1 TTD
Tip60-dependent acetylation of K16 of histone H4 has been
shown to reduce binding of the 53BP1 TTD to H4K20me2,
whereas H4 deacetylation facilities 53BP1 foci formation (Hsiao
and Mizzen, 2013; Tang et al., 2013). To compare the acetyl-
methyllysine switches in histone H4 and p53, we superimposed
structures of the TTD bound to p53K381acK382me2 and
H4K20me2 peptides (Figure 5A; Tang et al., 2013). The overlay2–331, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 327
Table 1. Data Collection and Refinement Statistics for the 53BP1
TTD-p53K381acK382me2 Complex
TTD-p53K381acK382me2
Data Collection
Wavelength (A˚) 1.000
Space group C2221
Resolution (A˚) 50–1.8 (1.84–1.80)
Cell dimensions (A˚) a = 58.89, b = 110.94,
c = 96.92
a = b = g = 90
No. of measured reflections 616,822
No. of unique reflections 29,571
Completeness (%) 100 (99.8)
Redundancy 7.3 (6.2)
I/s(I) 25.7 (2.4)
Rmerge (%) 7.7 (64.1)
Refinement
Resolution (A˚) 48.5–1.8 (1.87–1.8)
No. of reflections 28,055
R factor (%) 18.68 (25.5)
Rfree (%) 21.84 (30.0)
No. of protein atoms 2,085
No. of heterogeneous atoms 270
No. of water molecules 270
Root-mean-square deviations
from ideal values
Bond lengths (A˚) 0.007
Bond angles () 1.156
Average B values (A˚2)
Protein chain A/B 20.6/29.9
Peptide chain C/D 28.9/56.6
Water 34.0
Ramachandran plot analysis
Residues in most favored
regions
92.7%
Residues in additional allowed
regions
7.3%
Residues in generously allowed
regions
0
Residues in disallowed regions 0
Values in parentheses refer to data in the highest-resolution shell.
Rfree is calculated based on 5% of the reflections.reveals distinct mechanisms for the recognition of these se-
quences. Unlike the p53 peptide, which interacts primarily
with the first Tudor of TTD, the histone peptide forms a long
loop that spreads over both Tudors. 1H,15N HSQC titration ex-
periments confirmed the more extensive binding site for the
H4K20me2 peptide, with residues in the second Tudor exhibiting
substantial chemical shift changes upon binding to H4K20me2
(Figure 5B). Furthermore, K16 in the TTD-H4K20me2 complex
occupies a binding pocket positioned far from the binding
pocket for acetylated K381 of p53, suggesting that the histone
and p53 acetyl-methyllysine switches can modulate distinct328 Structure 23, 322–331, February 3, 2015 ª2015 Elsevier Ltd All r53BP1 activities and could also be selectively targeted. The rigid
structure of p53K381acK382me2 particularly allows for modular
design of small molecules to selectively disrupt the interaction.
We employed fixed distances between aC atoms of R379,
K381ac, and K382me2 and the helical turn as restraints to
develop three-point pharmacophores with high complemen-
tarity to the p53 peptide in charge, shape, and hydrophobicity
(see Supplemental Information).While the lead compound pyrro-
lino-quinolinol (PQ) binds to the TTD more weakly than does the
p53 peptide, at high concentrations it can displace the peptide,
and the pattern of chemical shift perturbations indicates that it
occupies the same binding pocket (Figures 5C and 5D; Figures
S4 and S5). We expect to increase affinity through mitigating
the entropic factor by incorporating shorter tethers in the suc-
ceeding generation of dual PTM mimetics.
Phosphorylation of p53 Affects Binding of 53BP1 TTD
The p53 sequence around K382 contains a number of PTMs
that are proposed to modulate binding of cofactors and/or
prevent deposition of other PTMs. These include phosphoryla-
tion of T377 and S378 and acetylation of K386. To determine
whether the neighboring PTMs affect binding of 53BP1 to
p53K382me2, we tested a glutathione S-transferase (GST)-
tagged TTD construct using a biotinylated p53 peptide microar-
ray (Table S1). As shown in Figure 6, the GST-TTD recognizes
p53K382me2, p53K381acK382me2, and p53K382me2K386ac
peptides but binds more weakly to p53T377pK382me2 and
p53S378pK382me2 peptides. The structure of the TTD-
p53K381acK382me2 complex provides insight into the inhibitory
effects of phosphorylation. The side chain of S378 is fully buried
in the groove formed by the D1521, M1584, and E1551 residues
of TTD, with the hydroxyl group of S378 donating a transient
hydrogen bond to the carboxyl group of E1551 (Figure 6C).
Phosphorylation of S378 would eliminate the hydrogen bond
as well as increase steric hindrance and repulsion between the
negatively charged phosphate group and the two negatively
charged carboxyl groups of E1551 and D1521. Phosphorylation
of T377 would be unfavorable for similar reasons. Although we
did not observe a clear electron density for T377 in the complex,
its position adjacent to S378 implies that T377 is bound in the
same well-defined groove (Figure 6C). While the contributions
of these individual PTMs to the p53 activity is still not fully under-
stood, the peptide microarray results suggest that phosphoryla-
tion of T377 and S378 may provide a mechanism for releasing
53BP1 from p53. The peptide microarray also demonstrated
that the TTD binds p53K370me2 and p53K372me2 peptides
more weakly (KD of 20 mM) than p53K382me2, corroborating
previous observations that 53BP1 TTD selects for dimethylated
p53K382 (Roy et al., 2010).
Concluding Remarks
Single PTMs of p53 have been shown to have an impact on tran-
scriptional and transcription-independent functions of p53
(Berger, 2010; Chuikov et al., 2004; Huang and Berger, 2008;
Huang et al., 2006, 2007, 2010; Kachirskaia et al., 2008; Shi
et al., 2007). However, characterization of cross-regulation or
combinatorial action of multiple dynamic marks on p53 remains
a daunting challenge. Multiple modifications can act synergisti-
cally to enhance the affinity and specificity of p53-bindingights reserved
Figure 5. Comparison of the Acetyl-Methyl-
lysine Switches
(A) Superimposition of the structures of the TTD in
complex with the p53K381acK382me2 (yellow) and
H4K20me2 (dark red) (PDB ID 2LVM) peptides. The
TTD from the p53K381acK382me2 complex is
shown with the K381ac- and K382me2-binding
pockets colored as in Figure 4. The TTD from the
H4K20me2 complex is omitted for clarity.
(B) Normalized chemical shift changes observed in
1H,15N HSQC spectra of TTD after addition of the
H4K20me2 peptide. The TTD/peptide ratio is 1:10.
(C) 1H,15N HSQC overlays of TTD in the free state
(black) and in the presence of 2 mM PQ (pink).
(D) Residues that exhibit significant PQ-induced
resonance perturbations in (C) are mapped onto the
surface of the 53BP1 TTD and labeled. The PQ
compound is shown as brown sticks and is docked
to TTD. PQ synthesis is described in Figure S4; see
also Figure S5.effectors or antagonistically to inhibit interactions. The first
evidence of a crosstalk between methylated and acetylated
lysine residues in the p53CTDwas reported in 2007. It was found
that DNA damage-induced monomethylation of p53K372
promotes acetylation of nearby K373 and K382, and prior
acetylation of K373 and K382 inhibits subsequent methyla-
tion of p53K372 by SET7/9 (Ivanov et al., 2007; Kurash et al.,
2008).
In this work, we examined the relationship between PTMs in
the K381K382 region and the surrounding residues of p53. Our
results demonstrate that dimethylation of p53K382 increasesFigure 6. The Effect of Neighboring PTMs on Binding of TTD
(A) Scatterplot of duplicate peptide microarray binding assays for GST 53BP1-TTD. The correlation coefficie
GraphPad Prism v5.
(B) Top: diagram of the p53 CTD and modifications studied. A, acetylation; M, methylation; P, phosphorylat
replicate array binding experiments are presented as normalized mean intensities on a color scale from 0
binding).
(C) The zoom-in view of the S378-binding site.
Structure 23, 322–331, February 3, 201notably within the first hour after DNA
damage and is subject to further regula-
tion, whereas the level of p53K381ac
does not change significantly. The dual
p53K381acK382me2 mark is robustly
recognized by the TTD domain of 53BP1
and weakly by BD of p300. We found
that the K381acK382me2 combination of PTMs induces
a large conformational change in the p53 CTD. Unlike
p53K382me2 peptide, which adopts a U-shaped conformation,
the p53K381acK382me2 peptide folds into an a helix when
bound to TTD, and the two binding sites in TTD only partially
overlap. These data suggest a possible mechanism for the
regulation of p53 activity, i.e. different combinations of PTMs
could promote distinct conformations of p53. The PTM-triggered
changes in the CTD structure can mediate p53 ability to selec-
tively interact with binding partners, facilitating p53 commitment
to specific biological processes, such as DNA repair.nt was calculated by linear regression analysis using
ion. Bottom: heatmaps depicting the results of four
(black; undetectable binding) to 1 (yellow; strong
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EXPERIMENTAL PROCEDURES
Dot-Blot Analysis of Antibody Specificity
The generation and purification of the rabbit polyclonal antibody specific
for p53 dimethylated at K382 was described previously (Kachirskaia
et al., 2008). The anti-p53K381ac antibody was obtained from Abcam
(ab61241; Abcam, Cambridge, MA). Peptides were dissolved in water to
yield stock solutions of 1 or 2 mg/ml. The peptides were further diluted
into 0.1% BSA in PBS. One microliter of the peptide dilutions was spotted
onto a Whatman Protran nitrocellulose membrane (0.45 mm pore size; GE
Healthcare Life Sciences, Pittsburgh, PA), allowed to air dry for 1 hr at
room temperature, and stored at 4C overnight. Membranes were blocked
with 1% BSA in PBS-T (PBS with 0.1% Tween 20) for 1 hr, incubated
with a 1:100 dilution of anti-p53K382me2 for 1 hr at 4C, then washed
five times with PBS-T. The membranes were incubated with horseradish
peroxidase-conjugated goat antirabbit secondary antibody (Thermo
Scientific, Rockford, IL) for 1 hr at room temperature with shaking, then
washed five times with PBS-T. Images were developed with ECL Plus
substrate (Thermo Scientific) and exposed to Hyperfilm ECL (GE Health-
care Life Sciences) or imaged using a ChemiDoc MP imaging system
(Bio-Rad).
Cell Culture, Immunoprecipitation, and Immunoblotting
The U2OS cell line was cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum. Subconfluent cultures were used for
experiments. Where indicated, cells were exposed to 5 or 10 Gy of IR from a
137Cs source using a Shepart Mark II irradiator, treated with 0.5 mg/ml doxo-
rubicin (Selleck Chemicals) for 4 hr or 400 nM TSA (Cell Signaling Technolo-
gies) for 1 hr. For cells treated with both agents, TSA was added 3 hr after
addition of doxorubicin and cells were harvested 1 hr later. Cells were rinsed
with ice-cold PBS and harvested by scraping, with the addition of protease
inhibitors to the last of three ice-cold PBS rinses. Protein extracts were pre-
pared by suspending cell pellets in lysis buffer (50 mM Tris-HCl [pH 7.4],
250 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM dithiothreitol, 1 mM
phenylmethanesulfonylfluoride [Sigma], protease inhibitors [Roche], and
phosphatase inhibitors), incubating on ice for 20 min, then centrifuged at
14,000 g at 4C for 10 min. Total protein was determined using a modified
Bradford method (Pierce). Lysates containing 1 mg of total protein were incu-
bated with anti-p53 DO1-conjugated agarose beads (Santa Cruz Biotech-
nology) on a rotating mixer overnight at 4C. Agarose beads were washed
three times with lysis buffer and suspended in 20 ml of 23 LDS sample buffer
(Life Technologies) without reducing agents, and heated for 10 min at 70C.
Eluted proteins were separated by denaturing gel electrophoresis and trans-
ferred to polyvinylidene fluoride membranes. Membranes were blocked as
described above and incubated with anti-p53K382me2 overnight at 4C.
Potential interference by immunoglobulin heavy chains was avoided by
use of an antirabbit light-chain-specific secondary antibody (Jackson
ImmunoResearch) for detection of p53 K382me2 or horseradish peroxi-
dase-conjugated DO1 anti-p53 (Santa Cruz Biotechnology) for detection of
total p53. Other reagents used include anti-p21 (Santa Cruz Biotechnologies)
and anti-p53 Ser15p (Cell Signaling Technologies). Specific bands were de-
tected by Western Lightning (PerkinElmer) or ECL Plus (Thermo Scientific)
chemiluminescence reagents.
Protein Crystallization and Structure Determination by X-Ray
Crystallography
53BP1 TTD (15mg/ml) was mixed with p53K381acK382me2 peptide in a 1:1.5
molar ratio on ice for 1 hr prior to crystallization. Crystals for crystallographic
analysis were obtained at 18C after extensive screening and optimization
using the hanging-drop vapor diffusion method. The optimized condition
contained 0.1 M sodium chloride and 4.0 M sodium formate in a 0.1 M
Tris-HCl (pH 7.5) buffer. The data were collected at 100 K on a NOIR-1 MBC
system detector at beamline 4.2.2 at the Advanced Light Source in Berkeley,
California, integrated and scaled using the HKL2000. The structure was ob-
tained by molecular replacement using the TTD structure (Protein Data Bank
ID [PDB] ID 3LGL) as a search model. The Refmac, Phenix-refine, and Coot
programs were used in the refinement. The crystallographic statistics are
shown in Table 1.330 Structure 23, 322–331, February 3, 2015 ª2015 Elsevier Ltd All rACCESSION NUMBERS
Atomic coordinates for the structure have been deposited in PDB under
accession code 4X34.
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